|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15121513151415151516151715181519152015211522...15771578» |
- calcitriol (BPM 31543) / BPGbio
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease (clinicaltrials.gov) - Dec 22, 2016
P1, N=30, Active, not recruiting, Sponsor: Berg, LLC
Recruiting --> Active, not recruiting | N=18 --> 30 | Trial primary completion date: Aug 2016 --> Jan 2017
- || adegramotide/nelatimotide (DSP-7888) / Sumitomo Pharma
Enrollment change, Metastases: A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 22, 2016
P1, N=76, Recruiting, Sponsor: Boston Biomedical, Inc
Recruiting --> Active, not recruiting | N=18 --> 30 | Trial primary completion date: Aug 2016 --> Jan 2017 N=60 --> 76
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Trial initiation date, Monotherapy, Tumor mutational burden, PD(L)-1 Biomarker, Surgery, Stroma, Metastases: NCI-2016-01004: Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 22, 2016
P2, N=40, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
N=60 --> 76 Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Dec 2016
- doxepin / Generic mfg.
Trial primary completion date: Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy (clinicaltrials.gov) - Dec 21, 2016
P=N/A, N=50, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Dec 2016 Trial primary completion date: Oct 2016 --> Oct 2017
- Trial primary completion date: ALCI2: Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma (clinicaltrials.gov) - Dec 20, 2016
P1, N=24, Recruiting, Sponsor: Catherine Bollard
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Nov 2016 --> Nov 2017
- temozolomide / Generic mfg., memantine / Generic mfg., mefloquine / Generic mfg.
Trial primary completion date: Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy (clinicaltrials.gov) - Dec 20, 2016
P1, N=144, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2016 --> Nov 2017 Trial primary completion date: Sep 2017 --> Sep 2018
- ||| Tazverik (tazemetostat) / Ipsen
Enrollment change: A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 20, 2016
P2, N=180, Recruiting, Sponsor: Epizyme, Inc.
Trial primary completion date: Sep 2017 --> Sep 2018 N=150 --> 180
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
New P3 trial, Metastases: LMS-04: Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma (clinicaltrials.gov) - Dec 20, 2016
P3, N=150, Active, not recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- New trial: CONDRO1: Low Grade Chondrosarcoma Versus Enchondroma (clinicaltrials.gov) - Dec 19, 2016
P=N/A, N=102, Completed, Sponsor: Istituto Ortopedico Rizzoli
- ganitumab (AMG 479) / Takeda, ImmunityBio
Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Dec 19, 2016
P3, N=330, Suspended, Sponsor: National Cancer Institute (NCI)
N=150 --> 180 Phase classification: P2 --> P3 | N=140 --> 330
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Tumor mutational burden: SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov) - Dec 19, 2016
P2, N=334, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P3 | N=140 --> 330 Phase classification: P=N/A --> P2
- Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, PD(L)-1 Biomarker, Surgery, Metastases: Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 15, 2016
P1/2, N=47, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Phase classification: P=N/A --> P2 Not yet recruiting --> Recruiting
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
New P2 trial, Metastases: MITO 26: Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) (clinicaltrials.gov) - Dec 15, 2016
P2, N=43, Not yet recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- ||||||| Rintega (rindopepimut) / Celldex
Trial completion: Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Dec 15, 2016
P3, N=745, Completed, Sponsor: Celldex Therapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas (clinicaltrials.gov) - Dec 15, 2016
P2, N=80, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- New trial: A Study to Compare Adjuvant Concurrent Chemoradiation (CCRT) to Adjuvant Radiation Therapy (RT) in Grade 2 and 3 Extremity Soft Tissue Sarcomas (clinicaltrials.gov) - Dec 15, 2016
P=N/A, N=80, Completed, Sponsor: Institut de Canc
- | cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 14, 2016
P2, N=0, Completed, Sponsor: University of Miami
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- | Tecentriq (atezolizumab) / Roche
New P2 trial, Metastases: SABR-PDL1: Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (clinicaltrials.gov) - Dec 14, 2016
P2, N=180, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
New P1/2 trial, Metastases: ADP-0011-007: Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma (clinicaltrials.gov) - Dec 14, 2016
P1/2, N=15, Recruiting, Sponsor: Adaptimmune
- Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Dec 13, 2016
P1, N=18, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Jun 2017
- Enrollment closed, Enrollment change, Metastases: NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy (clinicaltrials.gov) - Dec 13, 2016
P1, N=2, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Active, not recruiting | N=12 --> 2
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Enrollment change, Trial primary completion date: Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer (clinicaltrials.gov) - Dec 13, 2016
P3, N=23, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting | N=12 --> 2 Recruiting --> Active, not recruiting | N=30 --> 23 | Trial primary completion date: Sep 2017 --> Jan 2017
- ||| crenigacestat (LY3039478) / Eli Lilly, BMS
Enrollment open, Combination therapy, Metastases: A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 13, 2016
P1b, N=163, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=30 --> 23 | Trial primary completion date: Sep 2017 --> Jan 2017 Not yet recruiting --> Recruiting
- Enrollment change, Trial termination: Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST) (clinicaltrials.gov) - Dec 9, 2016
P=N/A, N=5, Terminated, Sponsor: Kliniken Ludwigsburg-Bietigheim gGmbH
Not yet recruiting --> Recruiting N=30 --> 5 | Recruiting --> Terminated; According to study protocol the trial was terminated because the recruitment of trial participants was insufficient.
- sapanisertib (CB-228) / Calithera
New P2 trial: Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas (clinicaltrials.gov) - Dec 9, 2016
P2, N=33, Not yet recruiting, Sponsor: Fox Chase Cancer Center
- ||||| enapotamab vedotin (HuMax-AXL-ADC) / Genmab
New P1/2 trial: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors (clinicaltrials.gov) - Dec 9, 2016
P1/2, N=165, Recruiting, Sponsor: Genmab
- |||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Metastases: Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours (clinicaltrials.gov) - Dec 9, 2016
P2, N=160, Recruiting, Sponsor: Canadian Cancer Trials Group
N=30 --> 5 | Recruiting --> Terminated; According to study protocol the trial was terminated because the recruitment of trial participants was insufficient. Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche
Trial primary completion date: Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus (clinicaltrials.gov) - Dec 8, 2016
P2, N=51, Completed, Sponsor: Gynecologic Oncology Group
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2009 --> Jul 2007
- ifosfamide / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New trial: EUROBOSS: European Study in Bone Sarcoma Patients Over 40 Years (clinicaltrials.gov) - Dec 8, 2016
P=N/A, N=100, Completed, Sponsor: Italian Sarcoma Group
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche
Trial completion: Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus (clinicaltrials.gov) - Dec 7, 2016
P2, N=51, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Jan 2009 --> Jul 2007 Active, not recruiting --> Completed
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Active, not recruiting --> Completed Trial primary completion date: May 2018 --> Dec 2018
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial primary completion date: Aerosolized Aldesleukin in Treating Patients With Lung Metastases (clinicaltrials.gov) - Dec 7, 2016
P1/2, N=56, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: May 2018 --> Dec 2018 Trial primary completion date: Jun 2017 --> Jun 2018
- Trial primary completion date, Metastases: NCI-2021-03446: Advanced Gastrointestinal Endoscopic Imaging (clinicaltrials.gov) - Dec 6, 2016
P=N/A, N=500, Suspended, Sponsor: Stanford University
Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: Jun 2014 --> Dec 2019
- melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment change, Trial withdrawal: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Dec 6, 2016
P1, N=0, Withdrawn, Sponsor: University of Louisville
Trial primary completion date: Jun 2014 --> Dec 2019 N=10 --> 0 | Recruiting --> Withdrawn
- tasadenoturev (DNX-2401) / DNAtrix
Enrollment closed: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Dec 6, 2016
P1b, N=37, Active, not recruiting, Sponsor: DNAtrix, Inc.
N=10 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Metastases: Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung (clinicaltrials.gov) - Dec 6, 2016
P2, N=35, Active, not recruiting, Sponsor: Vector Oncology
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Trial primary completion date: Ewing/Allo: Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma (clinicaltrials.gov) - Dec 6, 2016
P1, N=10, Completed, Sponsor: University of Louisville
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Apr 2020 --> Dec 2016
- New trial, IO biomarker, Surgery: Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer (clinicaltrials.gov) - Dec 5, 2016
P=N/A, N=42, Recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
- ||| enoblituzumab (MGA271) / MacroGenics
New P1 trial: Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors (clinicaltrials.gov) - Dec 5, 2016
P1, N=112, Not yet recruiting, Sponsor: MacroGenics
- | sorafenib / Generic mfg.
Enrollment closed: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis (clinicaltrials.gov) - Dec 5, 2016
P3, N=83, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | Trial primary completion date: Apr 2020 --> Dec 2016 Suspended --> Active, not recruiting
- Sutent (sunitinib) / Pfizer
Enrollment closed, HEOR, Metastases: Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST (clinicaltrials.gov) - Dec 5, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: Radboud University
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker, Metastases: A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma (clinicaltrials.gov) - Dec 4, 2016
P2, N=60, Not yet recruiting, Sponsor: Assaf-Harofeh Medical Center
- thiotepa / Generic mfg.
Enrollment closed, Enrollment change: OSII-TTP: Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma (clinicaltrials.gov) - Dec 2, 2016
P2, N=45, Active, not recruiting, Sponsor: Centre Leon Berard
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=66 --> 45
- zotiraciclib (TG02) / Cothera Biosci
Enrollment open: Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Dec 2, 2016
P2, N=152, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=66 --> 45 Not yet recruiting --> Recruiting
- |||||||||| carotuximab IV (ENV-105) / Kairos Pharma
New P3 trial, Metastases: TAPPAS: Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (clinicaltrials.gov) - Dec 2, 2016
P3, N=124, Not yet recruiting, Sponsor: Tracon Pharmaceuticals Inc.
- | sitravatinib (MGCD516) / BeiGene
New P2 trial, Metastases: AAAQ8661: Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas (clinicaltrials.gov) - Dec 1, 2016
P2, N=29, Recruiting, Sponsor: Gary Schwartz
- ||||| Enrollment closed, Surgery: AREN0534: Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor (clinicaltrials.gov) - Nov 30, 2016
P3, N=249, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting
- veliparib (ABT-888) / AbbVie
Combination therapy, PARP Biomarker: A071102: Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Nov 29, 2016
P2/3, N=440, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Recruiting --> Suspended
- || carotuximab IV (ENV-105) / Kairos Pharma
Phase classification, Trial primary completion date, Combination therapy, Metastases: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 29, 2016
P2a, N=94, Recruiting, Sponsor: Tracon Pharmaceuticals Inc.
Recruiting --> Suspended Phase classification: P1b --> P2a | Trial primary completion date: Jun 2016 --> Jun 2017
- |||| Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: ANNOUNCE: A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 25, 2016
P3, N=460, Active, not recruiting, Sponsor: Eli Lilly and Company
Phase classification: P1b --> P2a | Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Sep 2018 --> Mar 2019